India aims to clock USD 15.5 bn pharma exports in FY'13

The USD 25 billion target, however, for pharma exports in 2013-14 would be a challenging task in view of global slowdown, she added.

"Our industry has told us about the economic impacts on pharmaceutical orders especially from Africa and least developed countries where health campaigns have slowed down," Jain told PTI after addressing an Indian pharmaceutical seminar in Singapore.

"...it would be challenging to meet the USD 25 billion export target for 2013-14," she said.

The industry was in a position to capture other emerging opportunities, especially manufacturing of "off patent" products or products with expired patent, which would offset some of the decreases in orders, Jain added.

Underlining the Indian government's policy of "zero tolerance" on quality of pharma products, she said "track and trace barcodes" has been introduced on consignments exported to the global market as part of the ongoing promotions and quality assurances of "Made-in-India" products.

"We continue to stress on efficiency, efficacy and quality of the pharmaceutical products," said Jain.

The European and American markets accounted for 55 per cent of the Indian pharmaceutical product exports, reflecting that most of these products were made to the highest specification of the US Food and Drug Administration (USFDA).

"The export volumes to the European and US markets speak volume about the high quality of Indian

... contd.